Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
casdatifan + ipilimumab + zimberelimab
- Development stage
- Phase 1
- Lead developer
- Arcus Biosciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Casdatifan + ipilimumab + zimberelimab is an investigational triplet combination regimen being developed for the treatment of advanced clear cell renal cell carcinoma (ccRCC). The combination consists of casdatifan (AB521), an oral small-molecule inhibitor of hypoxia-inducible factor 2-alpha (HIF-2α); ipilimumab, an anti-CTLA-4 monoclonal antibody; and zimberelimab, an anti-PD-1 monoclonal antibody. This regimen is designed to combine HIF-2α inhibition with dual immune checkpoint blockade (anti-PD-1 and anti-CTLA-4) without the use of a tyrosine kinase inhibitor. It is being evaluated in the Phase 1 ARC-20 platform study (NCT05536141) in the first-line setting for patients with advanced ccRCC.
- Other names
- casdatifan + ipilimumab + zimberelimab regimencasdatifan plus ipilimumab plus zimberelimab
02
Targets
CD28 (Cluster of Differentiation 28)CD80 (T-lymphocyte activation antigen CD80)CD86 (T-lymphocyte activation antigen CD86)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)HIF1A (Hypoxia-inducible factor 1-alpha)ICOS (Inducible T-cell costimulator)PDCD1 (Programmed cell death protein 1 receptor)CD274 (Programmed cell death protein 1 ligand 1)PDCD1LG2 (Programmed cell death 1 ligand 2)EPAS1 (Hypoxia-inducible factor 2-alpha)
Beyond the preview
Go deeper on casdatifan + ipilimumab + zimberelimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on casdatifan + ipilimumab + zimberelimab.